HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma.

Context.--ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA...

Descripción completa

Detalles Bibliográficos

Publicado en:	Archives of Pathology & Laboratory Medicine Vol. 140; no. 12; pp. 1345 - 1364
Autores principales:	Bartley, Angela N., Washington, Mary Kay, Ventura, Christina B., Ismaila, Nofisat, Colasacco, Carol, Benson III, Al B., Carrato, Alfredo, Gulley, Margaret L., Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J., Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A.
Formato:	algorithm pictorial tables/charts Journal Article
Publicado:	College of American Pathologists Dec2016
Acceso en línea:	Ver este registro en EBSCOhost